BaseClear BV Certified to Provide NimbleGen Sequence Capture Services in the Netherlands
"We are very pleased to join the Roche NimbleGen CSP program, which complements our existing accreditations and certifications. BaseClear always strives to deliver the highest level of service to our customers", said Bas Reichert, commercial director of BaseClear. "I am proud that we are the first company in Europe as a Roche NimbleGen Certified Service Provider for SeqCap EZ Library. With the Nimblegen SeqCap EZ Exome capture system we can extend our service portfolio and will be able to deliver a high quality and cost effective solution to the human genetics research community. The certification is an additional guarantee for our high quality standard, clearly outlines our commitment to providing the best possible exome capture service, and ensures that we will have early access to new product variants and improvements."
"Roche NimbleGen is pleased to welcome BaseClear as the first European certified service provider of our SeqCap EZ application. BaseClear's commitment to high-quality genomic and sequencing services in the Netherlands is key in providing researchers with access to cutting edge genomic tools such as the NimbleGen SeqCap EZ Workflow in the Benelux region" said Dr. Frank Pitzer, CEO of Roche NimbleGen, Inc.
For more information about Roche NimbleGen, please visit www.nimblegen.com
About BaseClear BV
BaseClear is a leading genomic service provider based in Leiden, The Netherlands. Within our ISO/IEC 17025 accredited laboratory setting we offer services for DNA-based research, quality assurance and forensics. For all areas in which DNA plays a key role, BaseClear offers several services in the form of convenient and high-quality solutions that can be tailored exactly to customer wishes. For more information about BaseClear BV, please visit www.baseclear.com.
Roche Diagnostics Deutschland GmbH
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80'000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.